Evaluation of the safety and efficacy in linagliptin with type 2 diabetic patients receiving hemodialysis therapy

Evaluation of the safety and efficacy in linagliptin with type 2 diabetic patients receiving hemodialysis therapy - Evaluation of the safety and efficacy in linagliptin with type 2 diabetic patients receiving hemodialysis therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010099

Enrollment

Registered

2013-04-01

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Taking the linagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients receiving hemodialysis therapy

Exclusion criteria

Exclusion criteria: Patients who are inappropriate to use linagliptin

Design outcomes

Primary

Measure	Time frame
Episode of hypoglycemia at 12 weeks after the linagliptin treatment	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026